Cardiogenic shock associated with reversible dilated cardiomyopathy during therapy with regular doses of venlafaxine.
We report a cardiac complication in a patient treated with regular doses of venlafaxine. A 49-year-old man with prior normal cardiac function and stable chronic hepatitis C was treated for a major depressive disorder with usual doses of venlafaxine during an 8-month period until the occurrence of a cardiogenic shock in a context of dilated cardiomyopathy. Three months after withdrawal of the drug, the left ventricular ejection fraction returned to normal values. Cardiomyopathy is a rare complication with high doses of venlafaxine that was not previously reported in patients free of prior cardiac disease and cardiomyopathy and treated with usual doses (initially 150 mg daily; after 3 months, 75 mg daily). An objective assessment revealed that venlafaxine was probably implied in the subsequent development of cardiomyopathy when considering the Naranjo Probability Scale. Physicians who usually prescribe venlafaxine have to be briefed on such potential cardiac adverse effects even with usual doses.
Charniot
Jean-Christophe
JC
AP-HP Avicenne Hospital, Department of Cardiology, Université Paris 13, UFR SMBH, 125 Route de Stalingrad, 93009 Bobigny Cedex, France. jean-christophe.charniot@avc.aphp.fr
Vignat
Noelle
N
Monsuez
Jean-Jacques
JJ
Kidouche
Rachid
R
Avramova
Boryana
B
Artigou
Jean-Yves
JY
Albertini
Jean-Paul
JP
D002311:Cardiomyopathy, Dilated / Q000139:chemically induced*; D003511:Cyclohexanols / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D012770:Shock, Cardiogenic / Q000139:chemically induced*; D000069470:Venlafaxine Hydrochloride
D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride